Related Experiment Video

Updated: Jul 7, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K

HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation

Monika Graeser1,2,3, Oleg Gluz1,2,4

  • 1West German Study Group, Moenchengladbach, Germany.

Breast Care (Basel, Switzerland)
|December 21, 2023
PubMed
Abstract

Insights

Advances in HER2-positive (Human Epidermal Growth Factor Receptor 2) early breast cancer treatment have improved survival. Targeted therapies and de-escalation strategies are optimizing care for patients with HER2+ eBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • HER2-positive (Human Epidermal Growth Factor Receptor 2) breast cancer historically had a poor prognosis.
  • Targeted therapies have been developed to address this specific breast cancer subtype.
  • Treatment strategies are evolving with escalation and de-escalation approaches.

Purpose of the Study:

  • To review landmark clinical trials in the management of HER2-positive early breast cancer (eBC).
  • To highlight advancements in treatment and patient care for HER2+ eBC over the past two decades.

Main Methods:

  • Review of landmark clinical trials.
  • Analysis of treatment evolution and management strategies.
  • Examination of neoadjuvant and post-neoadjuvant settings.

Main Results:

  • Continuous research has led to prolonged survival for patients with early HER2+ eBC.
  • Post-neoadjuvant therapy improves outcomes for high-risk patients with residual disease.
  • Selected patients may avoid chemotherapy with modern anti-HER2 agents without compromising survival.

Conclusions:

  • Treatment advancements have significantly improved outcomes in HER2+ early breast cancer.
  • Personalized therapy approaches are emerging through biomarker identification.
  • Future research focuses on molecular heterogeneity for tailored treatments.
Keywords:
Breast neoplasmsERBB2 proteinHER2HumanNeoadjuvant therapyTrastuzumab

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:29

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

129

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
370
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529